Greenway Medical Technologies Now Covered by Sterne Agee (GWAY)

Sterne Agee assumed coverage on shares of Greenway Medical Technologies (NASDAQ: GWAY) in a research note issued on Tuesday, TheFlyOnTheWall.com reports. The firm set an “underperform” rating on the stock.

The analysts wrote, “While Greenway Medical has achieved admirable success with the 5-10 doctor practices over the past 5+ years, as the average size of physician practices rises, we do not think the company possesses enough scale to convince enterprise-size physician practices to use the company’s technologies/services. We believe consensus revenue and EBITDA estimates are too high and GWAY shares are overvalued. Re-initiate with an Underperform rating and $5 price target.”

Greenway Medical Technologies (NASDAQ: GWAY) traded down 4.17% on Tuesday, hitting $11.72. Greenway Medical Technologies has a 1-year low of $11.41 and a 1-year high of $19.65. The stock’s 50-day moving average is currently $12.68. The company has a market cap of $348.6 million and a price-to-earnings ratio of 643.68.

Greenway Medical Technologies (NASDAQ: GWAY) last released its earnings data on Monday, May 6th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.03. The company had revenue of $33.80 million for the quarter, compared to the consensus estimate of $38.56 million. During the same quarter last year, the company posted $0.08 earnings per share. Greenway Medical Technologies’s revenue was up 2.7% compared to the same quarter last year. Analysts expect that Greenway Medical Technologies will post $0.02 EPS for the current fiscal year.

A number of other analysts have also recently weighed in on GWAY. Analysts at B. Riley initiated coverage on shares of Greenway Medical Technologies in a research note to investors on Friday, May 31st. They set a “buy” rating on the stock. Separately, analysts at Zacks downgraded shares of Greenway Medical Technologies from a “neutral” rating to an “underperform” rating in a research note to investors on Tuesday, May 7th. They now have a $11.30 price target on the stock. Finally, analysts at TheStreet downgraded shares of Greenway Medical Technologies from a “hold” rating to a “sell” rating in a research note to investors on Monday, May 6th.

Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $16.43.

Greenway Medical Technologies, Inc. (NASDAQ: GWAY) is a provider of integrated information technology solutions and managed business services to ambulatory healthcare providers.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.